Uveal melanoma

Paola Queirolo, Graziano Caltabiano, Francesco Spagnolo

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Uveal melanoma is the most common primary intraocular tumor in adults with a reported annual incidence of 6.3 per million among whites, 0.9 among Hispanic and 0.24 among blacks. Activation of the MAPK pathway caused by somatic mutations in GNAQ or GNA11 seems to be strongly involved in the pathogenesis of uveal melanoma. Local treatments include enucleation or more conservative treatments such as brachytherapy and proton-beam external irradiation. No efficacy of any adjuvant therapy was observed. Locoregional treatments, such as hepatic intra-arterial chemotherapy and immunoembolization have been developed for uveal melanoma liver metastasis. Up to 50% of patients with primary uveal melanoma will ultimately develop distant metastasis, associated to a poor prognosis and no effective therapies. Several drugs, such as bevacizumab, ipilimumab, imatinib and MEK-inhibitors, are currently under investigation as single agents or in combination with chemotherapeutic drugs for the treatment of metastatic uveal melanoma.

Original languageEnglish
Title of host publicationEmerging Therapeutics for Melanoma
PublisherFuture Medicine Ltd.
Pages155-163
Number of pages9
ISBN (Print)9781780840321, 9781780841168
DOIs
Publication statusPublished - Jan 1 2012

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Uveal melanoma'. Together they form a unique fingerprint.

Cite this